Previous Close | 1.9100 |
Open | 1.9500 |
Bid | 1.9600 x 0 |
Ask | 2.0000 x 0 |
Day's Range | 1.9500 - 1.9900 |
52 Week Range | 1.5000 - 2.6700 |
Volume | |
Avg. Volume | 17,764 |
Market Cap | 116.771M |
Beta (5Y Monthly) | 1.57 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.3680 |
Earnings Date | Feb 27, 2023 - Mar 03, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 5.25 |
Vancouver, British Columbia--(Newsfile Corp. - November 17, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that the US Patent and Trade Office (USPTO) has issued US Patent No. 11,497,812 B2 Compositions and Methods for Inhibiting the Activity of LAR Family Phosphatases to Case Western Reserve University. NervGen has an exclusi
Vancouver, British Columbia--(Newsfile Corp. - November 15, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that the Company has granted 400,000 incentive stock options to directors of the Company exercisable at a price of $1.74 per share for a period of five years and that vest equally every three months over ...
Dosing completed in third dose cohort of multiple ascending dose (MAD) portion of Phase 1 clinical trial in postmenopausal femalesU.S. Food and Drug Administration (FDA) amendment of partial clinical hold allows for bridging cohorts of males and premenopausal females in the Phase 1 trial to commenceGlenn Ives appointed as Lead Independent DirectorVancouver, British Columbia--(Newsfile Corp. - November 14, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a cl